

Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus

The D:A:D Study

The Data Collection on Adverse Events of Anti-HIV Drugs Study Group*

Background: An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases.

Methods: We investigated the frequency of and risk factors associated with liver-related deaths in the Data Collection on Adverse Events of Anti-HIV Drugs study, which prospectively evaluated 76 893 person-years of follow-up in 23 441 HIV-infected persons. Multivariable Poisson regression analyses identified factors associated with liver-related, AIDS-related, and other causes of death.

Results: There were 1246 deaths (5.3%; 1.6 per 100 person-years); 14.5% were from liver-related causes. Of these, 16.9% had active hepatitis B virus (HBV), 66.1% had hepatitis C virus (HCV), and 7.1% had dual viral hepatitis coinfections. Predictors of liver-related deaths were latest CD4 cell count (adjusted relative rate [RR], 16.1; 95% confidence interval [CI], 8.1-31.7 for <50 vs \geq 500/ μ L), age (RR, 1.3; 95% CI, 1.2-1.4 per 5 years older), in-

travenous drug use (RR, 2.0; 95% CI, 1.2-3.4), HCV infection (RR, 6.7; 95% CI, 4.0-11.2), and active HBV infection (RR, 3.7; 95% CI, 2.4-5.9). Univariable analyses showed no relationship between cumulative years patients were receiving cART and liver-related death (RR, 1.00; 95% CI, 0.93-1.07). Adjustment for the most recent CD4 cell count and patient characteristics resulted in an increased risk of liver-related mortality per year of mono or dual antiretroviral therapy before cART (RR, 1.09; 95% CI, 1.02-1.16; P = .008) and per year of cART (RR, 1.11; 95% CI, 1.02-1.21; P = .02).

Conclusions: Liver-related death was the most frequent cause of non-AIDS-related death. We found a strong association between immunodeficiency and risk of liver-related death. Longer follow-up is required to investigate whether clinically significant treatment-associated liver-related mortality will develop.

Arch Intern Med. 2006;166:1632-1641

MORTALITY AMONG HUMAN immunodeficiency virus (HIV)-infected persons living in resource-rich countries has declined from 20 to 30 per 100 person-years before 1995, when combination antiretroviral therapy (cART) became available, to 2 to 5 per 100 person-years in recent years.^{1,2} Nevertheless, mortality rates remain high relative to uninfected persons, even in settings with access to therapy.³⁻⁵ The risk of death from AIDS may be related to therapeutic failure,⁶ late initiation of cART,⁷ interruption or refusal of cART, incomplete adherence, or drug resistance.

More than 50% of all deaths in HIV-infected persons receiving cART are now from causes other than AIDS.^{2,8-10} An increasing proportion of deaths are the re-

sult of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infections and intravenous drug and alcohol use. In addition, there is an increasing awareness of the potential toxic effects associated with prolonged cART. Although some adverse effects (eg, lactic acidosis) are now rarely observed owing to avoidance of specific drug combinations,^{11,12} long-term toxic effects possibly resulting from mitochondrial toxicity, type 2 diabetes mellitus, and cardiovascular disease have emerged.¹²⁻¹⁴ The effect of any cART-induced hepatotoxicity¹⁵⁻¹⁸ on the risk of liver-related mortality remains to be determined. We investigated the causes and frequency of death in a large multicenter cohort of HIV-infected individuals and assessed the relationships between liver-related deaths and HIV-associated immunodeficiency, HBV and HCV coinfections, and cART.

*Authors/Writing Committee: The authors/writing committee for the D:A:D Study Group are listed at the end of this article.

Group Information: The members of the D:A:D Study Group are listed on page 1638.

METHODS

DESIGN

The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study is a collaborative, observational study of 11 cohorts that includes 23 441 HIV-1–infected persons prospectively followed up at 188 clinics in Europe, the United States, and Australia.¹⁹ The study began in December 1999, and the latest follow-up for this analysis is February 2004. Although the primary end point of the study is myocardial infarction, other end points, including all deaths, are prospectively collected. Details of quality assurance, governance, and sponsorship have been published elsewhere.¹⁴

DATA COLLECTION

All the participants were under prospective follow-up in their individual cohorts at the time of enrollment in the D:A:D study. Standardized data collection forms containing sociodemographic, clinical, laboratory, and comprehensive antiretroviral and other medication information are completed at each site annually. Results of HBV and HCV serologic and viral load assessments, if available, have been collected since January 1, 2004 (including previously collected data by the participating cohorts). Information on cause of death was collected using a case report form and was reviewed and coded centrally at the study coordinating office.

END POINTS

Deaths were classified as “liver related” if clinical or autopsy diagnoses described hepatic failure (regardless of etiology), hepatocellular carcinoma in patients with end-stage liver disease, esophageal or other bleeding in the presence of end-stage liver disease, assumed medication-related hepatotoxicity resulting in hepatic failure without evidence of other etiologies of hepatic failure, or acute hepatic failure after acute bacterial or opportunistic infection in patients with previously known end-stage liver disease. Deaths due to opportunistic infections or malignancies according to the Centers for Disease Control and Prevention definition of clinical AIDS were classified as “AIDS related.” The category “non-AIDS malignancies” excluded AIDS-defining and hepatitis virus–associated malignancies.

STATISTICAL ANALYSIS

All the analyses were based on calculations of the incidence rate, defined as the number of deaths divided by the total person-years of follow-up. Follow-up began at enrollment in the D:A:D study and ceased on the date of death, February 1, 2004, or 6 months after the patient’s last cohort visit, whichever came first. Each person’s follow-up was divided into a series of consecutive 1-month periods, and his or her status regarding each explanatory variable was determined at the start of each month. Explanatory variables considered were sex, cohort, HIV transmission group, ethnicity (all fixed covariates that remained unchanged), age, body mass index, family history of cardiovascular disease, smoking status, previous cardiovascular event, HCV status (negative: seronegative, or seropositive but HCV RNA negative; positive: seropositive and HCV RNA positive or HCV RNA unknown; or not tested), HBV status (positive: active infection [HB surface antigen, HB e antigen, or HBV DNA positive]; positive: inactive infection [HB surface antigen negative, anti-HB e antibody positive, or HBV DNA negative]; vaccinated: anti-HB surface antigen positive only; or not tested),

latest available CD4 cell count, latest available HIV RNA level, and calendar year (all time updated so that the value used was that from the beginning of the month in question rather than that from the time of D:A:D enrollment). Poisson regression models were used to quantify the relationship between each factor and the rate of death from each cause.

Each cause of death was modeled separately in all the analyses, and, therefore, the characteristics of patients dying of each cause were compared with those of all other patients in the cohort (including those dying of other causes). To rule out the possible competing effects of death from another cause, all the analyses were repeated after excluding from each those who died of other causes (eg, for analyses of the factors associated with liver-related deaths, individuals dying of AIDS-related and other causes were excluded). The conclusions remained unchanged.

To investigate the relationship between increased exposure to cART and liver-related deaths, we initially fitted a univariable Poisson regression model with cART categorized as 0, less than 1, 1 to less than 2, 2 to less than 3, 3 to less than 4, 4 to less than 5, 5 to less than 6, and 6 or more years, and then years of cART was considered as a continuous covariate. Subsequent analyses controlled for time-updated exposure to mono or dual antiretroviral therapy (ART) initiated before cART, the nadir CD4 cell count (and all other variables described previously), and then the latest CD4 cell count. The nadir CD4 cell count, the latest CD4 cell count (both after log₂ transformation), and the latest HIV RNA level (after log₁₀ transformation) were included as continuous covariates in these analyses. Additional analyses considered cumulative exposure to cART and liver-related mortality after stratifying by the latest CD4 cell count and the patients’ HCV status and after lagging the CD4 cell count by 3 or 6 months (ie, taking the CD4 cell count value for any 1 month as the value held 3 [or 6] months ago rather than the latest value).

RESULTS

PATIENT CHARACTERISTICS

We followed up 23 441 persons for a median of 3.5 years (interquartile range [IQR], 3.1–3.8 years; 76 893 person-years of follow-up). Follow-up on 20.8% of the participants was censored 6 months after their last cohort visit. At enrollment in the D:A:D study, participants had a median age of 39 years (range, 34–45 years), and 24.1% were women. The median nadir CD4 cell count before enrollment was 200/μL (range, 1–2580/μL), and clinical AIDS had been diagnosed in 26.4% of the participants. A total of 22.5% of the patients were HCV positive, and 6.8% had active and 21.4% had inactive HBV infection. Hepatitis C virus positivity and active HBV infection were found in 1.6% of the patients. By February 1, 2004, 88.7% of the patients had received cART (median, 4.5 years; range, 2.3–6.3 years), of whom 48.1% had received monotherapy or dual combination therapy before initiating cART; 4.4% of the patients had received therapy with nucleoside reverse transcriptase inhibitors only, either as monotherapy or dual therapy or as part of triple nucleoside reverse transcriptase inhibitor combinations.

MORTALITY AND LATEST CD4 CELL COUNTS

A total of 1246 persons (5.3%) died (incidence, 1.62 per 100 person-years; 95% confidence interval [CI], 1.53–

Table 1. Death Rates per 100 Person-Years of Follow-up, Stratified by the Latest CD4 Cell Count*

CD4 Cell Count, μL	Follow-up, Person-Years	AIDS-Related Deaths		Liver-Related Deaths		All Other Deaths	
		No.	Rate (95% CI)	No.	Rate (95% CI)	No.	Rate (95% CI)
<50	1657	202	12.19 (10.51-13.87)	22	1.33 (0.77-1.88)	79	4.77 (3.72-5.82)
50-99	1711	50	2.92 (2.11-3.73)	21	1.23 (0.70-1.75)	52	3.04 (2.21-3.87)
100-199	6044	69	1.14 (0.87-1.41)	44	0.73 (0.51-0.94)	132	2.18 (1.81-2.56)
200-349	15 421	32	0.21 (0.14-0.28)	52	0.34 (0.25-0.43)	152	0.99 (0.83-1.14)
350-499	17 578	20	0.11 (0.07-0.18)	21	0.12 (0.07-0.17)	104	0.59 (0.48-0.71)
≥ 500	34 370	11	0.03 (0.02-0.06)	21	0.06 (0.04-0.09)	155	0.45 (0.38-0.52)
<200	9412	321	3.41 (3.04-3.78)	87	0.92 (0.73-1.12)	263	2.79 (2.46-3.13)
≥ 200	67 369	63	0.09 (0.07-0.12)	94	0.14 (0.11-0.17)	411	0.61 (0.55-0.67)
Total	76 781	384	0.50 (0.45-0.55)	181	0.24 (0.20-0.27)	674	0.88 (0.81-0.94)

Abbreviation: CI, confidence interval.

*Results of univariable Poisson regression analyses confirmed that the relationships between each cause of death and the latest CD4 cell count were all significant ($P < .001$). Of the total of 1246 deaths, 7 patients died and did not have a CD4 cell count at the time of death. They are included in the overall analysis but are not included in any analyses in which the CD4 cell count is included as a factor. In Table 1, anyone with a missing CD4 cell count was also excluded from calculations of person-years.

1.71 per 100 person-years) at a median age of 44 years (IQR, 38-52 years); 5.2% of those who died had never received ART. The most common causes of death were AIDS (31.1% of deaths; incidence, 0.51 per 100 person-years), liver-related diseases (14.5% of deaths; incidence, 0.24 per 100 person-years), cardiovascular or other heart diseases (11.0% of deaths; incidence, 0.18 per 100 person-years), and non-AIDS malignancies (9.4% of deaths; incidence, 0.15 per 100 person-years); 33.8% of deaths were from other causes (incidence, 0.55 per 100 person-years).

In the 1246 patients who died, the latest CD4 cell count before death was less than 50/ μL in 24.5% and less than 200/ μL in 54.2%. The latest CD4 cell count was measured a median of 10.7 weeks (IQR, 5.3-18.4 weeks) before death (in those with a latest CD4 cell count <200/ μL , the assessment was a median of 10.1 weeks [IQR, 5.3-18.3 weeks] before death, and in those with a latest CD4 cell count of $\geq 200/\mu\text{L}$, the assessment was 11.1 weeks [IQR, 5.1-18.6 weeks] before death). We found a strong relationship between the degree of cellular immunodeficiency and AIDS-related, liver-related, and all other deaths (**Table 1**).

CLINICAL PRESENTATION

We observed 181 liver-related deaths: 87 (48.1%) in patients with CD4 cell counts less than 200/ μL and 94 (51.9%) in those with CD4 cell counts of 200/ μL or greater. Autopsy results were available for 9.8% of these patients. The characteristics of persons who died are given in **Table 2**. Individuals who died of liver-related causes were more likely to have acquired HIV infection by intravenous drug use and were more likely to have documented HCV coinfection or active HBV coinfection or HCV and active HBV coinfection. The median nadir and latest CD4 cell counts of patients dying of liver-related causes were higher than those of patients dying of AIDS. Although a smaller proportion of patients had started cART with a low CD4 cell count, a greater proportion had received monotherapy or dual therapy before cART. They were equally likely to be receiving treatment with

an undetectable HIV RNA level at the time of death. Reported diagnoses at the time of death are summarized in **Table 3**. There were no differences in the characteristics of liver-related deaths between patients with CD4 cell counts less than 200/ μL vs 200/ μL or greater.

RISK FACTORS

There was a strong relationship between immunodeficiency and liver-related death after adjusting for other potential confounding variables (adjusted relative rates [RRs] of 16.06, 11.54, 7.14, 3.95, and 1.67 for those with latest CD4 cell counts of <50, 50-99, 100-199, 200-349, and 350-499/ μL , respectively, compared with CD4 cell counts $\geq 500/\mu\text{L}$) (**Figure 1**). Other independent predictors of liver-related death were older age (adjusted RR per 5 years, 1.32), HIV acquisition via intravenous drug use (adjusted RR, 2.01), HCV infection (adjusted RR, 6.66), and active HBV infection (adjusted RR, 3.73).

When the CD4 cell count and HIV RNA level were included in the model as continuous variables, a 2-fold lower CD4 cell count was associated with a 23% increased risk of liver-related death (adjusted relative hazard per 2-fold lower CD4 cell count, 1.23; 95% CI, 1.17-1.29; $P < .001$), and each log higher HIV RNA level was associated with an increased risk of 27% (relative hazard, 1.27; 95% CI, 1.13-1.43; $P < .001$). The effects of other factors in the model were unchanged after including the variables in this way.

A total of 578 patients (2.5%) had started HCV treatment, and 20 735 patients (88.5%) had used 1 of the 3 ART drugs (lamivudine, tenofovir disoproxil, or adefovir dipivoxil) also active against HBV infection. Sensitivity analyses adjusting for specific treatment of HCV or HBV infection did not substantially change the factors observed in the main model.

LIVER-RELATED DEATHS AND DURATION OF cART

Liver-related death rates according to duration of cART and stratified by the latest CD4 cell counts and HCV sta-

Table 2. Characteristics of Patients Who Died of AIDS-Related Causes, Liver-Related Causes, and Other Causes

Characteristic	Cause of Death		
	AIDS Related (n = 388)	Liver Related (n = 181)	Other (n = 677)
Male, %	78.4	73.8	82.6
Age at death, median (range), y	42 (23-82)	43 (29-82)	45 (22-84)
Mode of infection, %			
Homosexual contact	45.4	19.1	42.4
Intravenous drug use	20.4	59.6	29.8
Heterosexual contact	17.0	11.5	16.5
Other/not known	17.3	9.8	11.2
Ethnicity, %			
White	43.6	47.5	50.1
Black	16.5	5.5	12.3
Other	4.4	2.2	1.6
Missing	35.6	44.8	36.0
CD4 cell count, median (range), / μ L			
Nadir	19 (0-530)	102 (0-761)	108 (0-1150)
Before death	40 (0-957)	196 (6-1200)	266 (0-1878)
Previous AIDS before death, %	100.0	39.9	44.6
ART			
Never, %	5.9	2.7	5.3
At the time of death, %	55.2	61.2	65.1
HIV RNA <400 copies/mL, %	27.0	54.6	58.5
If not receiving treatment, median (range) days since stopping	116 (2-1276)	82 (2-765)	82 (2-2178)
Ever receiving monotherapy or dual therapy, %	57.2	77.6	58.6
Initiated ART with cART, %	36.9	19.7	36.0
Initiated ART with CD4 cell counts <200/ μ L, %	68.3	46.4	47.9
Treatment (any) duration, median (range), y	4.2 (0-15.1)	5.3 (0-14.4)	4.9 (0-14.7)
cART duration, median (range) y	2.7 (0-7.7)	3.2 (0-7.6)	3.5 (0-8.2)
Hepatitis virus coinfections, %			
HCV serologic tests positive*	23.7	66.1	33.4
HBV serologic tests positive, inactive infection†	17.8	20.2	23.3
HBV seropositive, active infection‡	8.5	16.9	10.0
HBV vaccinated‡	1.5	4.4	2.4
HCV seropositive and active HBV infection	8.0	7.1	2.7
HCV and HBV serologic tests both negative	38.9	3.8	24.8

Abbreviations: ART, antiretroviral therapy; cART, combination ART; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

*Not tested: 20.1%, 19.1%, and 22.7%, respectively.

†Not tested: 13.7%, 24.6%, and 19.5%, respectively. Active HBV indicates hepatitis B surface antigen positive or hepatitis B e antigen positive or, if available, HBV DNA positive.

‡Hepatitis B surface antigen antibodies positive only (ie, hepatitis B c antibody assessment available and negative).

Table 3. Reported Events at the Time of Liver-Related Death, Stratified by Last Measured CD4 Cell Count*

Event	CD4 Cell Count		Total (N = 181)
	<200/ μ L (n = 87)	\geq 200/ μ L (n = 94)	
Hepatic failure	60 (69.0)	62 (66.0)	122 (67.4)
Hepatocellular carcinoma	9 (10.3)	8 (8.5)	17 (9.4)
Bleeding			
Esophageal varices	9 (10.3)	12 (12.8)	21 (11.6)
Other bleeding or bleeding not specified	12 (13.8)	5 (5.3)	17 (9.4)
Assumed toxicity of medication	1 (1.1)	4 (4.3)	5 (2.8)
Concomitant infection or malignoma in end-stage liver disease			
Bacterial peritonitis	0	2 (2.1)	2 (1.1)
Pneumonia	5 (5.7)	4 (4.3)	9 (5.0)
Other bacterial infection	5 (5.7)	5 (5.3)	10 (5.5)
AIDS-defining illness	4 (4.6)	4 (4.3)	8 (4.4)
Other			
Pulmonary embolism	0	2 (2.1)	2 (1.1)
Rejection of liver transplant (cause of death)	1 (1.1)	0	1 (0.6)

*Data are given as number (percentage). Each patient can be coded with more than 1 event; 2 patients with unknown CD4 cell counts at the time of death are excluded from the analysis stratified by CD4 cell count.

tus are shown in **Figure 2**. Death rates remained stable during the first 7 years of cART. Univariable analyses confirmed that there was no relationship between cumulative cART and liver-related deaths either overall (RR, 1.00; 95% CI, 0.93-1.07 per year of exposure; $P = .93$) or in CD4 cell count (<200/ μ L: RR, 1.08; 95% CI, 0.96-1.20; $P = .20$; \geq 200/ μ L: RR, 0.98; 95% CI, 0.88-1.08; $P = .66$) or HCV (negative: RR, 0.99; 95% CI, 0.87-1.12; $P = .85$; positive: RR, 1.01; 95% CI, 0.92-1.10; $P = .82$) strata.

Adjustment for time-updated antiretroviral monotherapy or dual therapy initiated before cART, the nadir CD4 cell count (as a continuous \log_2 -transformed variable), and other clinical and demographic variables (Figure 1) modified the relationship with cART slightly (**Table 4**). Adjustment for the latest CD4 cell count, which allows for study of the effect of cumulative cART over and above any positive effects of cumulative cART on CD4 cell counts, resulted in an increased risk of liver-related mortality with longer exposure to cART (1.11; $P = .02$). The use of mono or dual ART before cART was associated with an increased risk of liver-related deaths, but adjustment for this variable did not modify the relationship between cART and liver-related deaths.

COMMENT

In this large prospective study, we found that AIDS-related disease still accounted for most deaths (31.1%), and liver disease was the most frequent non-AIDS-related cause (14.5%). There was a strong association between immunodeficiency and an elevated risk of liver-related and other non-AIDS-related deaths. Other strong




Figure 1. Results of multivariable Poisson regression analysis to identify factors independently associated with AIDS-related, liver-related, and other causes of death. Results are also adjusted for sex, ethnicity, human immunodeficiency virus load (stratified as <50, 51-500, 501-10 000, 10 001-100 000, 100 001-1 000 000, and >1 000 000 copies/mL), family history of heart disease, calendar year of death (1999-2000, 2001, 2002, or 2003-2004), and cohort, none of which were predictive of death. Definitions of hepatitis C virus (HCV) and hepatitis B virus (HBV) status are described in the "Methods" section. Body mass index was calculated as weight in kilograms divided by the square of height in meters. CVD indicates cardiovascular disease; IDU, intravenous drug use. Vertical dotted line represents reference=1.0; error bars, 95% confidence intervals.

associations with liver-related deaths were intravenous drug use, HCV infection, and active HBV infection. Many patients in the D:A:D study who died had initiated monotherapy or dual therapy at a time when cART was not available. Only a few of those who died had never received cART.

Liver-related deaths are largely a consequence of chronic HBV or HCV coinfection,^{9,10,20-24} although the association between HCV coinfection and increased mortality has not consistently been identified.^{25,26} More than 76% of the liver-related deaths in the present study were associated with infection with either HBV or HCV. Infection with HIV accelerates the progression of HCV disease to cirrhosis presumably by increasing hepatitis C viremia.^{27,28} Conversely, HCV may adversely affect HIV infection and reduce the effectiveness of cART,²⁹ although this remains controversial.^{30,31} Whereas HBV infection increases liver-related mortality in coinfecting persons, it does not seem to affect the progression of HIV or the response to cART.²³ Antiretroviral therapy

has been reported to reduce liver-related mortality in HCV-coinfecting persons,³² but we found no such effect.

In the present cohort, 2.7% of all liver-related deaths were reported to be directly associated with antiretroviral medication. The link with acute hepatotoxicities for some antiretroviral drugs is an undisputed but infrequent cause of mortality.^{15,16} In contrast, the possible long-term adverse effects of cART on hepatic function are controversial,^{15,17} although a recent study³³ found a 12% increase in liver-related deaths per year of cART. Medication-associated hepatotoxicity may be more frequent in HCV-coinfecting persons.^{15,34} The present results do not allow us to reach firm conclusions about any relationship between prolonged cART and liver-related death. Because a higher CD4 cell count is associated with a lower rate of liver death, cART might affect the liver death rate in at least 2 ways: (1) by increasing the CD4 cell count, and thus reducing the death rate and (2) by increasing the death rate due to putative long-term hepatotoxicity.




Figure 2. Rates of liver-related deaths per 100 person-years by duration of combination antiretroviral therapy (cART), stratified by CD4 cell count (A) and hepatitis C virus (HCV) status (B). Error bars represent 95% confidence intervals.

Table 4. Relationship Between ART per Year of Exposure and Liver-Related Deaths

Multivariable Analysis*	RR (95% CI) of Liver-Related Deaths per Year of ART			
	Mono/Dual ART	P Value	cART	P Value
Adjusted for variables in Figure 1 only	1.11 (1.04-1.18)	<.001	1.06 (0.98-1.15)	.17
Adjusted for nadir CD4 cell count	1.11 (1.04-1.18)	.002	1.06 (0.86-1.15)	.22
Adjusted for latest (time-updated) CD4 cell count	1.09 (1.02-1.16)	.008	1.11 (1.02-1.21)	.02

Abbreviations: ART, antiretroviral therapy (including 1 or 2 reverse transcriptase inhibitors); cART, combination ART (including either ≥ 1 protease inhibitors or a nonnucleoside reverse transcriptase inhibitor); CI, confidence interval; RR, relative rate.

*Multivariable analyses were also adjusted for all variables shown in Figure 1.

This analysis, which assessed the relationship between cumulative cART exposure and the liver death rate without accounting for follow-up CD4 cell counts, suggests no association. Thus, if either of the 2 possible effects is operating, then it may be negated by the other. In contrast, adjusting for the latest CD4 cell count, which can be interpreted as showing the remaining relationship between cART duration and liver-related mortality after the positive effects of therapy have been removed, showed an 11% (95% CI, 2%-21%; $P = .02$) increased rate of liver-related death per year of cART. Thus, there may be negative effects of cART on the liver in addition to the positive effects acting via CD4 cell count increases. However, the residual relationship was relatively modest and of borderline statistical significance, so it is difficult to rule out confounding. The use of mono or dual ART before cART was also an independent factor seen among liver-related deaths, but adjustment for this variable did not modify the relationship between cART and liver-related deaths. This finding, however, might suggest that the prolonged use of reverse transcriptase inhibitors is a risk fac-

tor for hepatotoxicity. Further follow-up and increasing numbers of liver-related deaths are needed before the mechanisms behind our results can be clarified.

Although it has been recognized that HIV infection considerably accelerates the progression of HCV disease,²⁷ we were surprised to find such a strong relationship between liver-related deaths and cellular immunodeficiency. Although HIV replication was also predictive of these deaths, more than half of those who died of liver disease had undetectable viral loads at the time of death. A similar relationship between immunosuppression and poorer outcome is also seen in HIV-uninfected, HCV-infected liver transplant recipients: more intense post-transplantation immunosuppression, following the use of corticosteroids and antiproliferative agents, leads to increased graft failure and progression to cirrhosis.³³ In these patients, treatment for rejection has been associated with diminished survival in HCV-infected but not HCV-seronegative recipients.³⁶

The present study has notable strengths, in particular its large size, broad geographic area, inclusion of a

D:A:D Steering Committee

Persons indicated with an asterisk in the following paragraphs and S. Collins (London, England), T. Mertenskoetter, MD (Middlesex, England), E. Loeliger, MD (Greenford, England), R. Tressler, MD, MS (New York, NY), and I. Weller, MD, FRCP (London). *D:A:D central coordination*: N. Friis-Møller, MD, PhD (Copenhagen, Denmark), S. W. Worm, MD (Copenhagen), C. A. Sabin, PhD (London), A. Sjøel, MD, PhD (Copenhagen) (verification of primary end point), and J. D. Lundgren, MD, DMSc (Copenhagen). *D:A:D data managers*: A. Sawitz, BA (Copenhagen) (coordinator), M. Rickenbach, MD (Lausanne, Switzerland), P. Pezzotti, DStat (Milan, Italy), E. Krum, RN, BSN, STAT (Minneapolis, Minn), L. Gras, MSc (Amsterdam, the Netherlands), E. Balestre, MPH (Bordeaux, France), A. Sundström, BA (Stockholm, Sweden), B. Poll, MSc (Brussels, Belgium), E. Fontas, MD (Nice, France), F. Torres, MD, PhD (Barcelona, Spain), K. Petoumenos, PhD (Sydney, Australia), and J. Kjær, BSc (Copenhagen).

Members of the 11 Cohorts

AIDS Therapy Evaluation Project Netherlands. *Central coordination*: F. de Wolf, S. Zaheri, and L. Gras (Amsterdam). *Participating physicians*: W. Bronsveld and M. E. Hillebrand-Haverkort (Alkmaar); J. M. Prins, J. C. Bos, J. K. M. Eeftinck Schattenkerk, S. E. Geerlings, M. H. Godfried, J. M. A. Lange, F. C. van Leth, S. H. Lowe, J. T. M. van der Meer, F. J. B. Nellen, K. Pogány, T. van der Poll, P. Reiss,* Th. A. Ruys, S. U. Sankatsing, R. Steingrover, G. van Twillert, M. van der Valk, M. G. A. van Vonderen, S. M. E. Vrouwenraets, M. van Vugt, F. W. M. N. Wit, A. van Eeden, J. H. ten Veen, P. S. van Dam, J. C. Roos, K. Brinkman, P. H. J. Frissen, H. M. Weigel, J. W. Mulder, E. C. M. van Gorp, P. L. Meenhorst, A. T. A. Mairuhu, J. Veenstra, S. A. Danner, M. A. Van Agtmael, F. A. P. Claessen, R. M. Perenboom, A. Rijkeboer, and M. van Vonderen (Amsterdam); C. Richter, J. van der Berg, and R. van Leusen (Arnhem); R. Vriesendorp, F. J. F. Jeurissen, R. H. Kauffmann, and E. L. W. Koger (The Hague); B. Bravenboer (Eindhoven); C. H. H. ten Napel and G. J. Kootstra (Enschede); H. G. Sprenger, W. M. A. J. Miesen, R. Doedens, and E. H. Scholvinck (Groningen); R. W. ten Kate (Haarlem); D. P. F. van Houte and M. Polee (Leeuwarden); F. P. Kroon, P. J. van den Broek, J. T. van Dissel, and E. F. Schippers (Leiden); G. Schreij, S. van de Geest, and A. Verbon (Maastricht); P. P. Koopmans, M. Keuter, F. Post, and A. J. A. M. van der Ven (Nijmegen); M. E. van der Ende, I. C. Gyssens, M. van der Feltz, J. G. den Hollander, S. de Marie, J. L. Nouwen, B. J. A. Rijnders, and T. E. M. S. de Vries (Rotterdam); J. R. Juttman, C. van de Heul, and M. E. E. van Kasteren (Tilburg); M. M. E. Schneider, M. J. M. Bonten, J. C. C. Borleffs, P. M. Ellerbroek, I. M. Hoepelman, C. A. J. J. Jaspers, I. Schouten, and C. A. M. Schurink (Utrecht); W. L. Blok and A. A. Tanis (Vlissingen); and P. H. P. Groeneveld (Zwolle).

Aquitaine (France). *Scientific committee*: R. Salamon (chair), J. Beylot, M. Dupon, M. Le Bras, J. L. Pellegrin, and J. M. Ragnaud. *Central coordination*: F. Dabis,* G. Chêne, H. Jacqmin-Gadda, R. Thiébaud, S. Lawson-Ayayi, V. Lavignolle, E. Balestre, M. J. Blaizeau, M. Decoin, A. M. Formaggio, S. Delveaux, S. Labarere, B. Uwamaliya, E. Vimard, L. Merchadou, G. Palmer, D. Touchard, D. Dutoit, F. Pereira, and B. Boulant (Bordeaux). *Participating physicians*: J. Beylot, P. Morlat, N. Bernard, M. Bonarek, F. Bonnet, B. Coadou, P. Gelie, D. Jaubert, C. Nouts, D. Lacoste, M. Dupon, H. Dutronc, G. Cipriano, S. Lafarie, I. Chossat, J. Y. Lacut, B. Leng, J. L. Pellegrin, P. Mercié, J. F. Viillard, I. Faure, P. Rispal, C. Cipriano, S. Tchamgoué, M. Le Bras, F. Djossou, D. Malvy, J. P. Pivetaud, J. M. Ragnaud, D. Chambon, C. De La Taille, T. Galperine, S. Lafarie, D. Neau, A. Ochoa, C. Beylot, M. S. Doutre, J. H. Bezian, J. F. Moreau, J. L. Taupin, C. Conri, J. Constans, P. Couzigou, L. Castera, H. Fleury, M. E. Lafon, B. Masquelier, I. Pellegrin, P. Trimoulet, F. Moreau, C. Mestre, C. Series, and A. Taytard (Bordeaux).

Australian HIV Observational Database. *Central coordination*: M. Law* and K. Petoumenos (Sydney, New South Wales). *Participating physicians*: J. Anderson, K. Lowe, A. Mijch, K. Watson, N. Roth, and H. Wood (Melbourne, Victoria); M. Bloch, A. Gowers, D. Baker, R. McFarlane, A. Carr, and D. Cooper (Sydney); J. Chuah and W. Fankhauser (Gold Coast, Queensland); and S. Mallal and J. Skett (Perth, Western Australia).

Barcelona Antiretroviral Surveillance Study (Spain). *Central coordination*: G. Calvo,* F. Torres, and S. Mateu (Barcelona). *Participating physicians*: P. Domingo, M. A. Sambeat, J. Gatell, E. Del Cacho, J. Cadafalch, and M. Fuster (Barcelona); and C. Codina, G. Sirera, and A. Vaqué (Badalona).

The Brussels St Pierre Cohort (Belgium). N. Clumeck, S. De Wit,* M. Gerard, K. Kabeya, D. Konopnicki, A. Libois, M. C. Payen, B. Poll, and Y. Van Laethem.

Community Programs for Clinical Research on AIDS (United States). *Central coordination*: J. Neaton, G. Bartsch, W. M. El-Sadr,* E. Krum, G. Thompson, and D. Wentworth (Minneapolis, Minn). *Participating physicians*: R. Luskin-Hawk (Chicago, Ill); E. Telzak (Bronx, NY); W. M. El-Sadr (New York, NY); D. I. Abrams (San Francisco, Calif); D. Cohn (Denver, Colo); N. Markowitz (Detroit, Mich); R. Arduino (Houston, Tex); D. Mushatt (New Orleans, La); G. Friedland (New Haven, Conn); G. Perez (Newark, NJ); E. Tedaldi (Philadelphia, Pa); E. Fisher (Richmond, Va); F. Gordin (Washington, DC); L. R. Crane (Detroit); J. Sampson (Portland, Ore); and J. Baxter (Camden, NJ).

(continued)

representative group of persons with HIV infection, and rigorous review and central coding of causes of death. Nonetheless, some specific causes of death are still too infrequent to permit an analysis of risk factors. In line with all clinical studies, only a small proportion of patients underwent autopsy after death, and many patients died outside a medical institution, hampering as-

essment of causes of death. Moreover, information on alcohol intake was not routinely available and could not be considered, although it is an important risk for liver disease.³⁷

There are a variety of clinical implications of these findings. First, the strong association between immunodeficiency and an elevated risk of liver-related death un-

EuroSIDA (Multinational). *Central coordination:* O. Kirk (Copenhagen),* C. H. Olsen (Copenhagen), A. Mocroft (London), A. N. Phillips (London),* and J. D. Lundgren (Copenhagen) (chair of the D:A:D steering committee).* *Participating countries and physicians:* Austria: N. Vetter (Vienna); Belarus: I. Karpov and A. Vassilenko (Minsk); Belgium: N. Clumeck, S. De Wit, and B. Poll (Brussels); R. Colebunders (Antwerp); Czech Republic: L. Machala and H. Rozsypal (Prague); D. Sedlacek (Plzen); Denmark: J. Nielsen, T. Benfield, J. Gerstoft, T. Katzenstein, A. B. E. Hansen, and P. Skinhøj (Copenhagen); C. Pedersen (Odense); Estonia: K. Zilmer (Tallinn); France: C. Katlama, J.-P. Viard, and P.-M. Girard (Paris); T. Saint-Marc and P. Vanhems (Lyon); C. Pradier (Nice); F. Dabis (Bordeaux); Germany: M. Dietrich, C. Manegold, J. van Lunzen, and H.-J. Stellbrink (Hamburg); S. Staszewski and M. Bieckel (Frankfurt); F. D. Goebel (München); G. Fätkenheuer (Cologne); J. Rockstroh (Bonn); R. E. Schmidt (Hannover); Greece: J. Kosmidis, P. Gargalianos, H. Sambatakou, J. Perdios, G. Panos, and A. Filandras (Athens); Hungary: D. Banhegyi (Budapest); Ireland: F. Mulcahy (Dublin); Israel: I. Yust, M. Burke, and D. Turner (Tel Aviv); S. Pollack and J. Hassoun (Haifa); Z. Sthoeger (Rehovot); S. Maayan (Jerusalem); Italy: S. Vella and A. Chiesi (Rome); C. Arici (Bergamo); R. Pristerá (Bolzano); F. Mazzotta and A. Gabbuti (Florence); R. Esposito and A. Bedini (Modena); A. Chirianni and E. Montesarchio (Naples); V. Vullo, P. Santopadre, P. Narciso, A. Antinori, P. Franci, and M. Zaccarelli (Rome); A. Lazzarin, A. Castagna, and A. D'Arminio Monforte (Milan); Latvia: L. Viksna (Riga). Lithuania: S. Chaplinskis (Vilnius); Luxembourg: R. Hemmer and T. Staub (Luxembourg); the Netherlands: P. Reiss (Amsterdam); Norway: J. Bruun, A. Maeland, and V. Ormaasen (Oslo); Poland: B. Knysz and J. Gasiorowski (Wroclaw); A. Horban (Warsaw); G. Prokopowicz and A. Wiercinska-Drapalo (Bialystok); A. Boron-Kaczmarek and M. Pynka (Szczecin); M. Beniowski and E. Mularska (Chorzow); H. Trocha (Gdansk); Portugal: F. Antunes, K. Mansinho, and F. Maltez (Lisbon); Romania: D. Duiculescu, V. Babes, and A. Streinu-Cercel (Bucharest); Russia: E. Vinogradova and A. Rakhmanova (St Petersburg); Serbia & Montenegro: D. Jevtovic (Belgrade); Slovakia: M. Mokráš and D. Staneková (Bratislava); Spain: J. González-Lahoz, M. Sanchez-Conde, T. García-Benayas, L. Martin-Carbonero, and V. Soriano (Madrid); B. Clotet, A. Jou, J. Conejero, L. Ruiz, and C. Tural (Badalona); J. M. Gatell, J. M. Miró, L. Zamora, P. Domingo, Mar Gutierrez, Gracia Mateo, and M. A. Sambeat (Barcelona); Sweden: A. Blaxhult, A. Karlsson, and P. Pehrson (Stockholm); Switzerland: B. Ledergerber and R. Weber (Zürich); P. Francioli and A. Telenti (Lausanne); B. Hirschel and V. Soravia-Dunand (Geneva); H. Furrer (Bern); Ukraine: E. Kravchenko and N. Chentsova (Kyiv); and United Kingdom: M. Fisher (Brighton, England); R. Brettell (Edinburgh, Scotland); S. Barton, A. M. Johnson, D. Mercey, M. Murphy, M. A. Johnson, J. Weber, and G. Scullard (London, England).

HivBivus (Sweden). *Central coordination:* L. Morfeldt,* G. Thulin, and A. Sundström (Stockholm). *Participating physicians:* B. Åkerlund (Huddinge); K. Koppell and A. Karlsson (Stockholm); and L. Flamholz and C. Håkangård (Malmö).

Italian Cohort Naive to Antiretrovirals (Italy). *Central coordination:* A. d'Arminio Monforte* and P. Pezzotti (Milan). *Participating physicians:* M. Moroni, A. d'Arminio Monforte, A. Cargnel, S. Merli, G. M. Vigevani, C. Pastecchia, A. Lazzarin, G. Morsica, L. Caggese, and C. Moiola (Milan); M. S. Mura and M. Mannazzu (Sassari); F. Suter and C. Arici (Bergamo); P. E. Manconi and P. Piano (Cagliari); F. Mazzotta and S. Lo Caputo (Florence); A. Poggio, and G. Bottari (Verbania); G. Pagano and A. Alessandrini (Genova); A. Scasso and A. Vincenti (Lucca); V. Abbadessa and S. Mancuso (Palermo); F. Alberici and A. Ruggieri (Piacenza); M. Arlotti and P. Ortolani (Rimini); F. De Lalla and G. Tositti (Vicenza); G. Cassola and R. Piscopo (Genova); E. Raise and F. Ebo (Venezia); F. Soscia and L. Tacconi (Latina); U. Tirelli and R. Cinelli (Aviano); D. Santoro and L. Pusterla (Como); G. Carosi and C. Torti (Brescia); G. Cadeo and D. Bertelli (Brescia); G. Carnevale and P. Citterio (Cremona); G. Filice and R. Bruno (Pavia); G. Di Perri, I. Arnaudo, P. Caramello, G. C. Orofino, M. L. Soranzo, and M. Bonasso (Torino); G. Rizzardini and S. Melzi (Busto Arsizio); F. Chiodo and V. Colangeli (Bologna); G. Magnani and M. Ursitti (Regio Emilia); F. Menichetti and C. Martinelli (Pisa); R. Esposito, C. Mussini (Modena); F. Ghinelli and L. Sighinolfi (Ferrara); O. Coronado (Bologna); G. Ballardini and E. Rizzo (Ravenna); M. Montroni and M. C. Braschi (Ancona); E. Petrelli and A. Cioppi (Pesaro); R. Cauda, A. De Luca, N. Petrosillo, P. Noto, P. Narciso, G. Bontempo, A. Antinori, R. Acinapura, G. Antonucci, P. De Longis, V. Vullo, and M. Lichtner (Roma); G. Pastore and N. Ladisa (Bari); A. Chirianni, R. Viglietti, M. Piazza, S. Nappa, N. Abrescia, and M. De Marco (Napoli); A. Colomba, T. Prestileo (Palermo); C. De Stefano and A. La Gala (Potenza); L. Cosco and A. Scerbo (Catanzaro); P. Grima and P. Tundo (Lecce); J. Vecchiet and M. D'Alessandro (Chieti); and B. Grisorio and S. Ferrara (Foggia).

The Nice HIV Cohort (France). *Central coordination:* C. Pradier,* E. Fontas, and C. Caissotti. *Participating physicians:* P. Dellamonica, L. Bentz, E. Bernard, F. De Salvador-Guillouet, J. Durant, V. Mondain-Miton, I. Perbost, B. Prouvost-Keller, P. Pugliese, V. Rahelinirina, P. M. Roger, and F. Vandenbos.

Swiss HIV Cohort Study. *Central Coordination:* P. Francioli (president of the Swiss HIV Cohort Study Group), M. Rickenbacher (head of data center) (Lausanne). *Investigators:* M. Battegay, H. Bucher, L. Elzi, P. Erb, T. Klimkait, and C. Rudin (Basel); S. Cattacin, M. Egger, H. J. Furrer, and M. Gorgievski (Bern); B. Hirschel, L. Kaiser, L. Perrin, and S. Yerly (Geneva); Ph. Bürgisser, M. Cavassini, F. Paccaud, G. Pantaleo, and A. Telenti (Lausanne); E. Bernasconi, J.-C. Piffaretti (Lugano); C. Kind, P. Schmid, and P. Vernazza (St Gall); J. Böni, R. Dubs, M. Fischer, M. Flepp, A. Fontana, H. Günthard, U. Lauper, B. Ledergerber, M. Opravil, J. Schüpbach, R. Speck, R. Weber,* A. Trkola (Zurich).

derlines the importance of HIV treatment strategies that prevent immunodeficiency. These findings suggest that the effect of immunodeficiency on the risk of these types of death remains present even in patients with CD4 cell counts of 200 to 500/ μ L. Future studies should explore the possible benefits and risks of starting ART at CD4 cell counts higher than currently recommended in pa-

tients with a known risk of liver-related death. Second, the question of if and when to treat hepatitis co-infections must consider the status of liver disease and the immune status. Third, treatment or prevention of illicit drug and alcohol use is particularly important in HCV-coinfected persons because these risks are associated with accelerated progression to liver cirrhosis.

In conclusion, although the pattern of death in HIV-infected persons has changed, mortality rates remain substantial. Liver diseases, mainly due to hepatitis virus infections, accounted for almost 15% of the deaths and were strongly associated with advanced immunodeficiency. There was no definite relationship between mortality and ART. The possibility of increased medication-related mortality cannot be excluded, but the CD4 cell count increases with cART seem to balance any adverse effects that exist. Combination ART has substantially improved the outcomes of HIV-infected persons with access to care.^{1,3-5} However, long-term studies of large cohorts are crucial for the systematic collection and analyses of clinical end points to investigate the relationships between immune function and end-organ failure^{8,38} and to recognize novel and late-emerging treatment-related toxic effects.

Accepted for Publication: May 6, 2006.

Authors/Writing Committee: The following members of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group take authorship responsibility for the D:A:D Study: Rainer Weber, MD; Caroline A. Sabin, PhD; Nina Friis-Møller, MD, PhD; Peter Reiss, MD, PhD; Wafaa M El-Sadr, MD, PhD; Ole Kirk, MD, DMSc; Francois Dabis, MD, PhD; Matthew G. Law, PhD; Christian Pradier, MD, PhD; Stephane De Wit, MD, PhD; Börje Åkerlund, MD; Gonzalo Calvo, MD; Antonella d'Arminio Monforte, MD, DMSc; Martin Rickenbach, MD; Bruno Ledergerber, PhD; Andrew N. Phillips, PhD; and Jens D. Lundgren, MD, DMSc.

Correspondence: Rainer Weber, MD, Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH-8091 Zurich, Switzerland (infweb@usz.unizh.ch).

Financial Disclosure: Dr Weber has received travel grants from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, Hoffman-LaRoche, and TRB Chemedica. Dr Sabin has received honoraria, travel grants, fees for consultancy, and fees for teaching from Gilead Sciences, Bristol-Myers Squibb, and GlaxoSmithKline in the past 5 years.

Funding/Support: This study was supported by the Oversight Committee for the Evaluation of Metabolic Complications of HAART, a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the Food and Drug Administration, the patient community, and all pharmaceutical companies with licensed anti-HIV drugs in the US market (Abbott Laboratories, Agouron Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co, Pfizer, and Hoffman-La Roche); by grant CURE/97-46486 from the Health Insurance Fund Council, Amstelveen, the Netherlands, to the AIDS Therapy Evaluation Project Netherlands; by a grant from the Agence Nationale de Recherches sur le SIDA (Action Coordonnée No.7, Cohortes) to the Aquitaine cohort; by the Commonwealth Department of Health and Ageing and a grant from the Australian National Council on AIDS, Hepatitis C and Related Diseases' Clinical Trials and Research Committee to the Australian HIV Observational Data-

base; by grant FIS 99/0887 from the Fondo de Investigación Sanitaria and grant FIPSE 3171/00 from the Fundación para la Investigación y la Prevención del SIDA en España to the Barcelona Antiretroviral Surveillance Study; by grants 5U01AI042170-10 and 5U01AI046362-03 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, to the Terry Beinr Community Programs for Clinical Research on AIDS; by grants CT94-1637 and CT97-2713 from the BIOMED 1 and BIOMED 2 programs, respectively, grant QLK2-2000-00773 from the fifth framework program of the European Commission, and grants from Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim, and Roche to the EuroSIDA study; by an unrestricted educational grant from Glaxo Wellcome, Italy, to the Italian Cohort Naive to Antiretrovirals; and by a grant from the Swiss National Science Foundation to the Swiss HIV Cohort Study.

REFERENCES

1. Palella FJ Jr, Delaney KM, Moorman AC, et al: HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med.* 1998;338:853-860.
2. Mocroft A, Brettle R, Kirk O, et al: Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. *AIDS.* 2002; 16:1663-1671.
3. Egger M, Hirschel B, Francioli P, et al; Swiss HIV Cohort Study. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. *BMJ.* 1997;315:1194-1199.
4. Ledergerber B, Egger M, Opravil M, et al: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: Swiss HIV Cohort Study. *Lancet.* 1999;353:863-868.
5. Sterne JA, Hernan MA, Ledergerber B, et al: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. *Lancet.* 2005;366:378-384.
6. Ledergerber B, Lundgren JD, Walker AS, et al: Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet.* 2004;364:51-62.
7. Sabin CA, Smith CJ, Gumley H, et al: Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. *AIDS.* 2004;18:2145-2151.
8. Valdez H, Chowdhry TK, Asaad R, et al: Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. *Clin Infect Dis.* 2001;32:1487-1493.
9. Lewden C, Salmon D, Morlat P, et al: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. *Int J Epidemiol.* 2005;34:121-130.
10. Salmon-Ceron D, Lewden C, Morlat P, et al: Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol.* 2005;42:799-805.
11. Imhof A, Ledergerber B, Gunthard HF, Haupts S, Weber R: Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? *Clin Infect Dis.* 2005;41:721-728.
12. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. *Lancet.* 2000;356:1423-1430.
13. Brinkman K, Smeitink JA, Romijn JA, Reiss P: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. *Lancet.* 1999;354:1112-1115.
14. Friis-Møller N, Sabin CA, Weber R, et al: Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med.* 2003;349:1993-2003.
15. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA.* 2000;283:74-80.
16. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. *Hepatology.* 2002;35:182-189.

17. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. *Hepatology*. 2005;41:123-131.
18. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfecting with HIV and hepatitis C virus. *AIDS*. 2005;19:585-592.
19. Friis-Moller N, Weber R, Reiss P, et al; DAD Study Group. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy: results from the DAD study. *AIDS*. 2003;17:1179-1193.
20. Lewden C, Raffi F, Cuzin L, et al. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study): the Antiproteases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study. *J Infect Dis*. 2002;186:710-714.
21. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). *AIDS*. 2003;17:1803-1809.
22. Braitstein P, Yip B, Montessori V, Moore D, Montaner JS, Hogg RS. Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. *CMAJ*. 2005;173:160-164.
23. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. *AIDS*. 2005;19:593-601.
24. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet*. 2002;360:1921-1926.
25. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. *Clin Infect Dis*. 2004;39:1507-1513.
26. Hershov RC, O'Driscoll PT, Handelsman E, et al. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. *Clin Infect Dis*. 2005;40:859-867.
27. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. *J Hepatol*. 1997;26:1-5.
28. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. *Ann Intern Med*. 2003;138:197-207.
29. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet*. 2000;356:1800-1805.
30. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. *JAMA*. 2002;288:199-206.
31. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis*. 2005;192:992-1002.
32. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. *Lancet*. 2003;362:1708-1713.
33. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? *AIDS*. 2005;19:2117-2125.
34. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2001;27:426-431.
35. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. *Hepatology*. 1998;28:823-830.
36. Brown RS. Hepatitis C and liver transplantation. *Nature*. 2005;436:973-978.
37. Cainelli F, Concia E, Vento S. Mortality due to hepatitis C virus-related cirrhosis in patients infected with HIV type 1: a role for alcohol. *Clin Infect Dis*. 2001;33:1795-1797.
38. Sabin CA. The role of observational studies in assessing the impact of antiviral therapies. *Curr Opin Infect Dis*. 2000;13:631-635.

Correction

Error in Table. In the Original Investigation by Farber et al titled “Physicians’ Decisions to Withhold and Withdraw Life-Sustaining Treatment” published in the March 13 issue of the ARCHIVES (2006;166:560-564), there is an error in the Table. For the entry “A loved one or you has/have life-threatening illness,” the correct number (percentage) of respondents answering yes is 58 (14).